C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma - A data from multi-institutional study in Japan.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
11 2019
Historique:
received: 19 12 2018
revised: 08 03 2019
accepted: 08 04 2019
pubmed: 6 5 2019
medline: 20 8 2020
entrez: 5 5 2019
Statut: ppublish

Résumé

The C-reactive protein to albumin ratio (CAR) has been shown to provide prognostic information in several cancers. The objective in the study is to examine the prognostic value of CAR in patients with RCC who underwent nephrectomy. The record data from multi-institutional study of 1,028 patients was analyzed in the study. The cut-off value of the CAR was defined by receive operating characteristic (ROC) analysis. Overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) were evaluated, and univariate and multivariate analyses were conducted to assess the predictive value of the variables including CAR. The optimal cut-off value of 0.073 in CAR was defined according to the ROC analysis. The AUC in CAR for CSS was greater than that of NLR and PLR, and that for RFS was also greater than GPS and mGPS. Multivariate analysis demonstrated that the CAR was an independent prognostic factor for OS (P < 0.001), CSS (P < 0.001) in total cohort and RFS (P = 0.029) in nonmetastatic cohort. The findings of the present study suggested that the preoperative CAR is an independent prognostic indicator of OS, CSS and RFS for patients with RCC. Since CAR can be assessed prior to surgery, clinicians should this take into account for the treatment decision making.

Identifiants

pubmed: 31053528
pii: S1078-1439(19)30135-8
doi: 10.1016/j.urolonc.2019.04.002
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Serum Albumin 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

812.e1-812.e8

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Takuya Tsujino (T)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Kazumasa Komura (K)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan; Translational Research Program, Osaka Medical College, Takatsuki City, Osaka, Japan. Electronic address: uro051@osaka-med.ac.jp.

Takeshi Hashimoto (T)

Department of Urology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

Ryu Muraoka (R)

Department of Urology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

Naoya Satake (N)

Department of Urology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

Tomohisa Matsunaga (T)

Department of Urology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

Takeshi Tsutsumi (T)

Department of Urology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

Yuki Yoshikawa (Y)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Tomoaki Takai (T)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Koichiro Minami (K)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Hirofumi Uehara (H)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Hajime Hirano (H)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Hayahito Nomi (H)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Naokazu Ibuki (N)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Kiyoshi Takahara (K)

Department of Urology, Fujita-Health University School of Medicine, , Toyoake, Aichi, Japan.

Teruo Inamoto (T)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Yoshio Ohno (Y)

Department of Urology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

Haruhito Azuma (H)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH